Abstract 2405: Telmisartan Reduces the Six Months Late Lumen Loss and Inflammatory Markers After Sirolimus-Eluting Stent Implantation in Hypertensive Patients
Background: Telmisartan is an angiotensin receptor blocker and is well-known for its selective PPAR- γ activity. The purpose of this study was to compare the effect of telmisartan and valsartan on the late lumen loss and inflammatory markers after sirolimus-eluting stent (SES) implantation in hypertensive patients.
Methods: This was a randomized, prospective, single-blinded 6-month follow-up study including hypertensive patients with significant coronary artery stenosis (stenosis of > 70 percent of the lumen diameter) assigned to the Telmisartan Group (n=45) and the Valsartan Group (n=46). Patients with previously untreated de novo atherosclerotic lesions were treated with SESs.
Results: Risk factors such as diabetes, smoking, and obesity were similar in both groups at baseline. During the six-month follow-up period, only the Telmisartan Group showed significant decreases in inflammatory markers (Table⇓). The deltas (the difference between the six-month and baseline concentrations) in total cholesterol and LDL-cholesterol levels were significantly greater in the Telmisartan Group (Table⇓). The increase in adiponectin levels from baseline to six-month was significantly greater in the Telmisartan Group compared with the Valsartan Group (2.06 ± 2.73 μg/ml vs. 0.46 ± 2.08 μg/ml, p<0.05, respectively). Moreover, the late lumen loss was significantly lower in the Telmisartan Group compared with the Valsartan Group (0.16 ± 0.40 mm vs. 0.45 ± 0.61 mm, p<0.05, respectively). Major adverse cardiac events (death, myocardial infarction, and the need for repeated target lesion revascularization) were similar between the 2 groups [6.7% (n=3) in the Telmisartan Group and 8.7% (n=4) in the Valsartan Group (p=0.51)].
Conclusion: Telmisartan compared with valsartan was associated with significant decrease in the late lumen loss and inflammatory markers after SES implantation in hypertensive patients with significant coronary lesions.